Abbott Laboratories announced on Monday, Jan. 1, a $7.9 billion deal to buy Alere Inc., a provider of point-of-care testing that has spent the past several months streamlining operations following a management shake-up. Alere shares, listed on the New York Stock Exchange, soared more than 45% to about $54 in morning trading on Monday, assigning the target a market capitalization of about $4.66 billion. Terms of the agreement call for the Abbott Park, Ill., acquirer to pay $56 a share for Alere, implying a premium of more than 50% over the $37.20 price that Alere shares closed at on Friday, the last trading day before the deal's announcement. The acquisition equates to a total equity value of $5.8 billion at closing, according to Monday's announcement.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.